- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00628927
An Eval of Neurocognitive Function, Oxidative Damage, and Their Association With Outcomes in METH and Cocaine Abusers.
An Evaluation of Neurocognitive Function, Oxidative Damage, and Their Association With Treatment Outcomes in Methamphetamine and Cocaine Abusers
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
The primary objective of this study is to replicate the finding that performance on the Stroop color-word interference task is predictive of treatment completion in participants with cocaine use disorders and to extend this finding to participants with Methamphetamine use disorders. Secondary objectives include evaluating whether:
- performance on various neurocognitive measures, including the Stroop, Rey Auditory-Verbal Learning Test (RAVLT), Iowa Gambling Task (GT), Wisconsin Card Sorting Task (WCST), the Barratt Impulsiveness Scale version -11 (BIS-11), and the Frontal Systems Behavior Scale (FrSBe) is predictive of treatment attrition and stimulant use outcomes in METH/cocaine abusers;
- neurocognitive test performance is associated with oxidative damage, a severe consequence of oxidative stress, in METH/cocaine abusers;
- oxidative damage is predictive of treatment attrition and substance use outcomes in METH/cocaine abusers,
- oxidative damage in METH/cocaine abusers is significantly greater than that of a normal comparison group and
- exploratory analyses reveal a significant relationship among oxidative stress, neurocognitive function, and treatment outcomes in METH/cocaine abusers.
Studientyp
Einschreibung (Tatsächlich)
Kontakte und Standorte
Studienorte
-
-
Florida
-
Jacksonville, Florida, Vereinigte Staaten, 32211
- Gateway Community Services
-
-
Ohio
-
Columbus, Ohio, Vereinigte Staaten, 43207
- Maryhaven
-
-
Oregon
-
'Eugene, Oregon, Vereinigte Staaten, 97402
- Willamette Family Treatment Services
-
Portland, Oregon, Vereinigte Staaten, 97292
- ChangePoint, Inc.
-
-
Texas
-
Dallas, Texas, Vereinigte Staaten, 75228
- Nexus Recovery Center
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98122
- Recovery Centers of King County
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria (METH and/or Cocaine Dependent Group):
- be randomized into the CTN-0031 (STAGE-12) trial
- current abuse or dependence for METH and/or cocaine
- endorse METH and/or cocaine as the primary drug of choice
- able to correctly distinguish the colored stimuli on the Stoop task.
Exclusion Criteria (METH and/or Cocaine Dependent Group):
- history of stroke
- history of a seizure disorder
Inclusion Criteria (Non-METH and/or Cocaine Dependent Group):
- be 18 years of age or older
- be able to understand the study and provide written informed consent in English
Exclusion Criteria (Non-METH and/or Cocaine Dependent Group):
- history of stroke
- history of a seizure disorder
- positive urine toxicology screen
- screen positive for Major Depressive Syndrome, other Depressive Syndrome, Panic Syndrome, or other Anxiety Syndrome
- meet criteria for ADHD
- have HIV/AIDS
- history of an injury in which consciousness was lost for more than 30 minutes
- meet DSM-IV criteria for dependence (either current or lifetime) for any psychoactive substance other than nicotine or for abuse (both current and lifetime) for any psychoactive substance other than nicotine or for alcohol for which a life-time history of abuse is allowed
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: Fallkontrolle
- Zeitperspektiven: Querschnitt
Kohorten und Interventionen
Gruppe / Kohorte |
|---|
|
METH and/or cocaine dependent group
The METH and/or cocaine dependent group were also enrolled in CTN0031 (NCT00573183) and seeking treatment.
This group will be analyzed based on whether or not they completed treatment as defined by the study.
|
|
Non METH and/or cocaine dependent group
The Non METH and/or cocaine dependent group participants are normal controls recruited from the community.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Stroop Color-word Task
Zeitfenster: Single study visit
|
The primary objective of this study was to replicate the finding that performance on the Stroop color-word interference task is predictive of treatment completion in participants with cocaine use disorders (Streeter et al., 2007) and to extend this finding to participants with methamphetamine use disorders.
In the Stroop, the participant is required to name the color of the ink in which a word is printed while inhibiting the overlearned response of reading the word (e.g., the word ''red'' might be printed in blue ink).
The number of errors were subtracted from the time required (RT; Reaction Time) for each of the 3 trials, yielding three summary scores.
The derived interference score is obtained by subtracting the RT for the first trial from the RT for the third trial.
|
Single study visit
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Barrett Impulsiveness Scale Version 11 (BIS-11)
Zeitfenster: Single study visit
|
The BIS-11 consists of 30 self-report items, with responses in a four-point Likert-type scale (0 - 3)ranging from "Rarely/Never" to "Almost Always/Always" and comprises three domains: Attentional impulsiveness (AI), Motor impulsiveness (MI), and Non-planning impulsiveness (NP); these three domains are summed to yield a total score; higher scores reflect greater impulsivity.
The total score was utilized as the BIS-11 predictor measure (possible score range 0 - 90).
|
Single study visit
|
|
Tail Length From the Comet Assay for Oxidative Damage
Zeitfenster: Single study visit
|
The test for oxidative damage was derived from a blood sample which was analyzed for tail length from the comet assay; higher scores reflect greater oxidative damage.
|
Single study visit
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Theresa Winhusen, Ph.D., University of Cincinnati
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Winhusen TM, Somoza EC, Lewis DF, Kropp FB, Horigian VE, Adinoff B. Frontal systems deficits in stimulant-dependent patients: evidence of pre-illness dysfunction and relationship to treatment response. Drug Alcohol Depend. 2013 Jan 1;127(1-3):94-100. doi: 10.1016/j.drugalcdep.2012.06.017. Epub 2012 Jul 6.
- Winhusen T, Walker J, Brigham G, Lewis D, Somoza E, Theobald J, Somoza V. Preliminary evaluation of a model of stimulant use, oxidative damage and executive dysfunction. Am J Drug Alcohol Abuse. 2013 Jul;39(4):227-34. doi: 10.3109/00952990.2013.798663. Epub 2013 Jun 28.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
- NIDA-CTN-0031A
- U10DA013732 (US NIH Stipendium/Vertrag)
- 5U10DA013732 (US NIH Stipendium/Vertrag)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .